Tamoxifen resistant and refractory breast cancer: The value of aromatase inhibitors

Drugs

Volumn 62, Issue 6, 2002, Pages 957-966

  Goss, Paul E ^a   Strasser, Kathrin ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Medizinische Abteilung mit Onkologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL; PYRIDOGLUTETHIMIDE; TAMOXIFEN; VOROZOLE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RESISTANCE; CARCINOMA IN SITU; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GENE MUTATION; HUMAN; PATIENT COMPLIANCE; REVIEW;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; TAMOXIFEN; TREATMENT FAILURE;

EID: 0036235382     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262060-00007     Document Type: Review

References (56)

1. Role of extraglandular estrogen in human endocrinology
2. Aromatase expression in health and disease
3. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
4. Pharmacology of new aromatase inhibitors
5. Resistance of the ovary to blockade of aromatization with aminoglutethimide
6. The potential of aromatase inhibitors in breast cancer prevention
7. Concentration of sex steroids in adipose tissue after menopause
8. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer
9. Oestradiol synthesis from C19 steroids by human breast cancers
10. A reassessment of the role of breast tumor aromatization
11. Biological significance of aromatase activity in human breast tumors
12. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
13. Aberrant expression of aromatase in breast cancer tissues
14. Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies
15. The importance of local synthesis of estrogen within the breast
16. Regulation of aromatase activity within the breast
17. Aromatase inhibitors and their antitumor effects in model systems
18. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities
19. Aromatase overexpression and breast hyperplasia, an in vivo model -continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands
20. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells
21. Relationship between tumour aromatase activity, tumour characteristics and response to therapy
22. Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging
23. Aromatase inhibitors-mechanisms of steroidal inhibitors
24. Aromatase inhibitors-mechanisms for non-steroidal inhibitors
25. Pharmacology of inhibitors of estrogen biosynthesis
26. Aromatase inhibitors: Rationale for use following anti-oestrogen therapy
27. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
28. Peptide antagonists of the human estrogen receptor
29. Estrogen receptor variants in clinical breast cancer
30. An analysis of tamoxifen-stimulated carcinomas for mutations in the AF-2 region of the estrogen receptor
31. Oestrogen receptor mutants and variants in breast cancer
32. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
33. Status of aromatase inhibitors in relation to other breast cancer treatment modalities
34. Clinical significance of tamoxifen withdrawal response
35. Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer
36. Medical and surgical adrenalectomy in patients with advanced breast carcinoma
37. Current perspectives on aromatase inhibitors in breast cancer
38. Identification of a promoter and silencer at the 3′-end of the first intron of the human aromatase gene
39. A randomised trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer
40. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer
41. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
42. Anastrozole, a potent and selective aromatase inhibitor, versus megestrole acetate in postmenopausal women with advanced breast cancer: Results of overview and analysis of two phase III clinical trials
43. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
44. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
45. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
46. A phase III trial comparing vorozole (RIVIZORTM) versus aminoglutethimide in the treatment of advanced postmenopausal breast cancer
47. Vorozole (RivizorTM) versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen
48. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
49. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
50. Fadrozole HCl (CGS-1649A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomised double-blind controlled multiinstitutional trials
51. Formestan versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross-over trial of second-line hormonal treatment - The Swiss Group for Clinical Cancer Research
52. Tamoxifen (TAM) vs aminoglutethimide in breast cancer patients previously treated with adjuvant TAM. Preliminary results of a multicentric comparative study
53. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
54. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
55. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized multicenter study